Müller T - Search Results

1

Targeting repulsive guidance molecule A to promote regeneration and neuroprotection in multiple sclerosis.

Demicheva E, Cui YF, Bardwell P, Barghorn S, Kron M, Meyer AH, Schmidt M, Gerlach B, Leddy M, Barlow E, O'Connor E, Choi CH, Huang L, Veldman GM, Rus H, Shabanzadeh AP, Tassew NG, Monnier PP, Müller T, Calabresi PA, Schoemaker H, Mueller BK. Demicheva E, et al. Among authors: muller t. Cell Rep. 2015 Mar 24;10(11):1887-98. doi: 10.1016/j.celrep.2015.02.048. Cell Rep. 2015. PMID: 25801027 Free article.

2

Decreased levels of repulsive guidance molecule A in association with beneficial effects of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients.

Müller T, Barghorn S, Lütge S, Haas T, Mueller R, Gerlach B, Öhm G, Eilert K, Trommer I, Mueller BK. Müller T, et al. J Neural Transm (Vienna). 2015 Jun;122(6):841-8. doi: 10.1007/s00702-014-1308-x. Epub 2014 Sep 11. J Neural Transm (Vienna). 2015. PMID: 25209051

3

Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson's disease.

Müller T, Trommer I, Muhlack S, Mueller BK. Müller T, et al. J Neural Transm (Vienna). 2016 Apr;123(4):401-6. doi: 10.1007/s00702-016-1519-4. Epub 2016 Feb 15. J Neural Transm (Vienna). 2016. PMID: 26880022 Clinical Trial.

4

Perspective: Treatment for Disease Modification in Chronic Neurodegeneration.

Müller T, Mueller BK, Riederer P. Müller T, et al. Cells. 2021 Apr 12;10(4):873. doi: 10.3390/cells10040873. Cells. 2021. PMID: 33921342 Free PMC article. Review.

5

Photoreceptor layer thinning in idiopathic Parkinson's disease.

Roth NM, Saidha S, Zimmermann H, Brandt AU, Isensee J, Benkhellouf-Rutkowska A, Dornauer M, Kühn AA, Müller T, Calabresi PA, Paul F. Roth NM, et al. Among authors: muller t. Mov Disord. 2014 Aug;29(9):1163-70. doi: 10.1002/mds.25896. Epub 2014 Apr 30. Mov Disord. 2014. PMID: 24789530

6

Role of intraspinal steroid application in patients with multiple sclerosis.

Müller T. Müller T. Expert Rev Neurother. 2009 Sep;9(9):1279-87. doi: 10.1586/ern.09.60. Expert Rev Neurother. 2009. PMID: 19769444 Review.

7

Efficacy of mitoxantrone and intrathecal triamcinolone acetonide treatment in chronic progressive multiple sclerosis patients.

Hellwig K, Schimrigk S, Lukas C, Hoffmann V, Brune N, Przuntek H, Müller T. Hellwig K, et al. Among authors: muller t. Clin Neuropharmacol. 2006 Sep-Oct;29(5):286-91. doi: 10.1097/01.WNF.0000229545.81245.A4. Clin Neuropharmacol. 2006. PMID: 16960474 Clinical Trial.

8

Efficacy of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients with spinal symptoms.

Hellwig K, Stein FJ, Przuntek H, Müller T. Hellwig K, et al. Among authors: muller t. BMC Neurol. 2004 Nov 7;4(1):18. doi: 10.1186/1471-2377-4-18. BMC Neurol. 2004. PMID: 15530171 Free PMC article. Clinical Trial.

9

Reduction in the free radical status and clinical benefit of repeated intrathecal triamcinolone acetonide application in patients with progressive multiple sclerosis.

Müller T, Herrling T, Lütge S, Küchler M, Lohse L, Rothe H, Haas T, Marg M, Öhm G, Jung K. Müller T, et al. Clin Neuropharmacol. 2014 Jan-Feb;37(1):22-5. doi: 10.1097/WNF.0000000000000015. Clin Neuropharmacol. 2014. PMID: 24434528

10

Efficacy and safety of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients.

Hoffmann V, Schimrigk S, Islamova S, Hellwig K, Lukas C, Brune N, Pöhlau D, Przuntek H, Müller T. Hoffmann V, et al. Among authors: muller t. J Neurol Sci. 2003 Jul 15;211(1-2):81-4. doi: 10.1016/s0022-510x(03)00060-1. J Neurol Sci. 2003. PMID: 12767502 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,376 results

Search Page